ArticleMolecular and cellular pediatrics2026
miR223, miR30e, and miR30a show associations with perinatal metabolic acidosis in neonates with hypoxic-ischemic encephalopathy.
Article in Molecular and cellular pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05986994 (Role of microRNAs as Diagnostic and Prognostic Biomarkers of Neonatal Perinatal Asphyxia and Hypoxic Ischemic Encephalopathy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of microRNAs as Diagnostic and Prognostic Biomarkers of Neonatal Perinatal Asphyxia and Hypoxic Ischemic Encephalopathy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveHypoxic-Ischemic Encephalopathy (HIE) is a leading cause of neonatal death and long-term disabilities, leading researchers to explore novel candidate biomarkers to improve early diagnosis and guide treatment strategies. miR223, miR30a and miR30e have attracted attention as potential biomarkers for HIE due to its involvement in key cellular processes like inflammation, cell death, and neuroprotection. The rationale of this study was to examine longitudinal maternal and infant circulating miRNA blood levels from T0–T3 to 48 h of life in relation to perinatal metabolic acidosis and neonatal hypoxic–ischemic encephalopathy status. STUDY
designA prospective observational cohort study involving newborns born from September 2023 to September 2024 was carried out. Healthy newborns were assigned as control group (CG), those with pH < 7.12 without inclusion criteria for hypothermic treatment were assigned to no hypothermic treatment group (NHTG) those that met inclusion criteria for hypothermic treatment were included in the hypothermic treatment group (HTG). Blood samples of the newborns were collected by umbilical cord artery along with maternal venous blood at birth (T0), at 3 (T3) and 48 (T48) hours after birth, the latter were collected from capillary blood.
resultsOur results demonstrated consistent upregulation of miR223, miR30e and miR30a at T0 and T3 in NHTG and HTG. Interestingly, miR223 and miR30a were upregulated also in samples obtained by NHTG and HTG mother blood.
conclusionIn this exploratory analysis, miR223, miR30e, and miR30a were found to be associated with perinatal metabolic acidosis and acute hypoxic stress, as defined by cord blood pH and clinical HIE status at presentation, supporting their role as candidate markers of early postnatal response. CLINICAL
trial registrationNCT05986994, Identification of a Pool of MiRNA to Improve Early Management of Perinatal Asphyxia and Hypoxic Ischemic Encephalopathy Prospectively Registered on 14 August 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.